$27.16
1.38% yesterday
Nasdaq, Jun 27, 10:17 pm CET
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Moderna Stock price

$27.16
+0.40 1.49% 1M
-12.97 32.32% 6M
-14.42 34.68% YTD
-94.02 77.59% 1Y
-118.20 81.32% 3Y
-34.92 56.25% 5Y
+8.56 46.02% 10Y
+8.56 46.02% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.38 1.38%
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Key metrics

Basic
Market capitalization
$10.5b
Enterprise Value
$4.6b
Net debt
$-5.9b
Cash
$6.0b
Shares outstanding
387.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.31 | 4.92
EV/Sales
1.45 | 2.15
EV/FCF
negative
P/B
1.04
Financial Health
Equity Ratio
77.08%
Return on Equity
-32.67%
ROCE
-29.42%
ROIC
-52.18%
Debt/Equity
0.01
Financials (TTM | estimate)
Revenue
$3.2b | $2.1b
EBITDA
$-3.1b | $-4.0b
EBIT
$-3.3b
Net Income
$-3.4b | $-4.0b
Free Cash Flow
$-4.0b
Growth (TTM | estimate)
Revenue
-38.35% | -34.02%
EBITDA
27.33% | -22.66%
EBIT
32.09%
Net Income
43.75% | -12.36%
Free Cash Flow
-9.86%
Margin (TTM | estimate)
Gross
68.68%
EBITDA
-96.76% | -187.36%
EBIT
-102.80%
Net
-105.67% | -187.41%
Free Cash Flow
-126.98%
More
EPS
$-8.71
FCF per Share
$-10.42
Short interest
22.82%
Employees
5.80k
Rev per Employee
$560.00k
Show more

Is Moderna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Moderna Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Moderna forecast:

4x Buy
13%
20x Hold
65%
7x Sell
23%

Analyst Opinions

31 Analysts have issued a Moderna forecast:

Buy
13%
Hold
65%
Sell
23%

Financial data from Moderna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3,177 3,177
38% 38%
100%
- Direct Costs 995 995
73% 73%
31%
2,182 2,182
47% 47%
69%
- Selling and Administrative Expenses 1,112 1,112
27% 27%
35%
- Research and Development Expense 4,336 4,336
9% 9%
136%
-3,074 -3,074
27% 27%
-97%
- Depreciation and Amortization 192 192
67% 67%
6%
EBIT (Operating Income) EBIT -3,266 -3,266
32% 32%
-103%
Net Profit -3,357 -3,357
44% 44%
-106%

In millions USD.

Don't miss a Thing! We will send you all news about Moderna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moderna Stock News

Neutral
Seeking Alpha
12 days ago
Moderna, Inc. (NASDAQ:MRNA ) Barclays Speaking the Science Call Series Call June 16, 2025 10:00 AM ET Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Rose Loughlin - Executive Vice President of Research Conference Call Participants Huidong Wang - Barclays Bank PLC, Research Division Huidong Wang My name is Gena Wang. I'm SMID Cap biotech analyst at the Barclays.
Negative
Reuters
15 days ago
Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.
Positive
Reuters
16 days ago
The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of high-risk adults aged 18 to 59 years.
More Moderna News

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Stéphane Bancel
Employees 5,800
Founded 2010
Website www.modernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today